|
1
|
Grassi W, De Angelis R, Lamanna G and
Cervini C: The clinical features of rheumatoid arthritis. Eur J
Radiol. 27(Suppl 1): S18–S24. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jacobson DL, Gange SJ, Rose NR and Graham
NM: Epidemiology and estimated population burden of selected
autoimmune diseases in the United States. Clin Immunol
Immunopathol. 84:223–243. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kahlenberg JM and Fox DA: Advances in the
medical treatment of rheumatoid arthritis. Hand Clin. 27:11–20.
2011. View Article : Google Scholar :
|
|
4
|
Demoruelle MK, Deane KD and Holers VM:
When and where does inflammation begin in rheumatoid arthritis?
Curr Opin Rheumatol. 26:64–71. 2014. View Article : Google Scholar :
|
|
5
|
Nielen MM, van Schaardenburg D, Reesink
HW, Twisk JW, van de Stadt RJ, van der Horst-Bruinsma IE, de Gast
T, Habibuw MR, Vandenbroucke JP and Dijkmans BA: Increased levels
of C-reactive protein in serum from blood donors before the onset
of rheumatoid arthritis. Arthritis Rheum. 50:2423–2427. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Masson-Bessière C, Sebbag M, Durieux JJ,
Nogueira L, Vincent C, Girbal-Neuhauser E, Durroux R, Cantagrel A
and Serre G: In the rheumatoid pannus, anti-filaggrin
autoantibodies are produced by local plasma cells and constitute a
higher proportion of IgG than in synovial fluid and serum. Clin Exp
Immunol. 119:544–552. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Snir O, Widhe M, Hermansson M, von Spee C,
Lindberg J, Hensen S, Lundberg K, Engström A, Venables PJ, Toes RE,
et al: Antibodies to several citrullinated antigens are enriched in
the joints of rheumatoid arthritis patients. Arthritis Rheum.
62:44–52. 2010. View Article : Google Scholar
|
|
8
|
Murray CJ, Vos T, Lozano R, Naghavi M,
Flaxman AD, Michaud C, Ezzati M, Shibuya K, Salomon JA, Abdalla S,
et al: Disability-adjusted life years (DALYs) for 291 diseases and
injuries in 21 regions, 1990–2010: A systematic analysis for the
Global Burden of Disease Study 2010. Lancet. 380:2197–2223. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gibofsky A: Overview of epidemiology,
pathophysiology, and diagnosis of rheumatoid arthritis. Am J Manag
Care. 18(Suppl 13): S295–S302. 2012.
|
|
10
|
Cross M, Smith E, Hoy D, Carmona L, Wolfe
F, Vos T, Williams B, Gabriel S, Lassere M, Johns N, et al: The
global burden of rheumatoid arthritis: Estimates from the global
burden of disease 2010 study. Ann Rheum Dis. 73:1316–1322. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Clough J: The Cleveland Clinic Guide to
Arthritis. Kaplan Publishing; New York, NY: 2009
|
|
12
|
van Oosterhout M, Bajema I, Levarht EW,
Toes RE, Huizinga TW and van Laar JM: Differences in synovial
tissue infiltrates between anti-cyclic citrullinated
peptide-positive rheumatoid arthritis and anti-cyclic citrullinated
peptide-negative rheumatoid arthritis. Arthritis Rheum. 58:53–60.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
van der Helm-van Mil AH and Huizinga TW:
Advances in the genetics of rheumatoid arthritis point to
subclassification into distinct disease subsets. Arthritis Res
Ther. 10:2052008. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Scott DL, Wolfe F and Huizinga TW:
Rheumatoid arthritis. Lancet. 376:1094–1108. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Eastgate JA, Symons JA, Wood NC,
Grinlinton FM, di Giovine FS and Duff GW: Correlation of plasma
interleukin 1 levels with disease activity in rheumatoid arthritis.
Lancet. 2:706–709. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Feldmann M, Brennan FM and Maini RN:
Brennan, FM, and Maini, RN Rheumatoid Arthritis. Cell.
85:1277–1289. 1996. View Article : Google Scholar
|
|
17
|
Choy EH, Isenberg DA, Garrood T, Farrow S,
Ioannou Y, Bird H, Cheung N, Williams B, Hazleman B, Price R, et
al: Therapeutic benefit of blocking interleukin-6 activity with an
anti-interleukin-6 receptor monoclonal antibody in rheumatoid
arthritis: A randomized, double-blind, placebo-controlled,
dose-escalation trial. Arthritis Rheum. 46:3143–3150. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
van Roon JA, van Roy JL, Gmelig-Meyling
FH, Lafeber FP and Bijlsma JW: Prevention and reversal of cartilage
degradation in rheumatoid arthritis by interleukin-10 and
interleukin-4. Arthritis Rheum. 39:829–835. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Smolen JS, Landewé R, Breedveld FC, Buch
M, Burmester G, Dougados M, Emery P, Gaujoux-Viala C, Gossec L, Nam
J, et al: EULAR recommendations for the management of rheumatoid
arthritis with synthetic and biological disease-modifying
anti-rheumatic drugs: 2013 update. Ann Rheum Dis. 73:492–509. 2014.
View Article : Google Scholar
|
|
20
|
Smolen JS, van der Heijde D, Machold KP,
Aletaha D and Landewé R: Proposal for a new nomenclature of
disease-modifying antirheumatic drugs. Ann Rheum Dis. 73:3–5. 2014.
View Article : Google Scholar
|
|
21
|
Smolen JS, Aletaha D, Koeller M, Weisman
MH and Emery P: New therapies for treatment of rheumatoid
arthritis. Lancet. 370:1861–1874. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Dcodhar S, Sethi R and Srimal R:
Preliminary study on anti-rheumatic activity of curcumin
(diferuloyl methane). Indian J Med Res. 71:632–634. 1980.
|
|
23
|
Kuttan G, Hari Kumar K, Guruvayoorappan C
and Kuttan R: Antitumor, anti-invasion, and antimetastatic effects
of curcumin. The Molecular Targets and Therapeutic Uses of Curcumin
in Health and Disease. Aggarwal BB, Surh YJ and Shishodia S:
Springel; New York, NY: pp. 173–184. 2007, View Article : Google Scholar
|
|
24
|
Lev-Ari S, Strier L, Kazanov D, Elkayam O,
Lichtenberg D, Caspi D and Arber N: Curcumin synergistically
potentiates the growth-inhibitory and pro-apoptotic effects of
celecoxib in osteoarthritis synovial adherent cells. Rheumatology
(Oxford). 45:171–177. 2006. View Article : Google Scholar
|
|
25
|
Joe B, Rao UJ and Lokesh BR: Presence of
an acidic glycoprotein in the serum of arthritic rats: Modulation
by capsaicin and curcumin. Mol Cell Biochem. 169:125–134. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Newton R and Holden N: Inhibitors of 38
mitogen-activated protein kinase: Potential as anti-inflammatory
agents in asthma? BioDrugs. 17:113–129. 2003. View Article : Google Scholar
|
|
27
|
Guex N and Peitsch MC: SWISS-MODEL and the
Swiss-PdbViewer: an environment for comparative protein modeling.
Electrophoresis. 18:2714–2723. 1997. View Article : Google Scholar
|
|
28
|
Morris GM, Huey R, Lindstrom W, Sanner MF,
Belew RK, Goodsell DS and Olson AJ: AutoDock4 and AutoDockTools4:
Automated docking with selective receptor flexibility. J Comput
Chem. 30:2785–2791. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Discovery Studio, version 3.5: Accelrys
Inc; San Diego, CA, USA: 2012
|
|
30
|
Hess B, Bekker H, Berendsen HJ and Fraaije
JG: LINCS: A linear constraint solver for molecular simulations. J
Comput Chem. 18:1463–1472. 1997. View Article : Google Scholar
|
|
31
|
Hess B, Kutzner C, van der Spoel D and
Lindahl E: GROMACS 4: Algorithms for highly efficient,
load-balanced, and scalable molecular simulation. J Chem Theory
Comput. 4:435–447. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Schüttelkopf AW and van Aalten DM: PRODRG:
A tool for high-throughput crystallography of protein-ligand
complexes. Acta Crystallogr D Biol Crystallogr. 60:1355–1363. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Essmann U, Perera L, Berkowitz ML, Darden
T, Lee H and Pedersen LG: A smooth particle mesh Ewald method. J
Chem Phys. 103:8577–8593. 1995. View Article : Google Scholar
|
|
34
|
DeLano WL: The PyMOL Molecular Graphics
System. World Wide Web. http://www.pymol.org.
2002
|
|
35
|
Humphrey W, Dalke A and Schulten K: VMD:
Visual molecular dynamics. J Mol Graph. 14:33–38. 27–28. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Laskowski RA and Swindells MB: LigPlot+:
Multiple ligand-protein interaction diagrams for drug discovery. J
Chem Inf Model. 51:2778–2786. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Turner P: XMGRACE, version 5.1.19. Center
for Coastal and Land-Margin Research. Oregon Graduate Institute of
Science and Technology; Beaverton, OR: 2005
|
|
38
|
Kumari R, Kumar R and Lynn A: Open Source
Drug Discovery Consortium: g_mmpbsa - a GROMACS tool for
high-throughput MM-PBSA calculations. J Chem Inf Model.
54:1951–1962. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Baker NA, Sept D, Joseph S, Holst MJ and
McCammon JA: Electrostatics of nanosystems: Application to
microtubules and the ribosome. Proc Natl Acad Sci USA.
98:10037–10041. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Amadei A, Linssen AB and Berendsen HJ:
Essential dynamics of proteins. Proteins. 17:412–425. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Chikan NA and Vipperla B: KAISO
inhibition: An atomic insight. J Biomol Struct Dyn. 33:1794–1804.
2015. View Article : Google Scholar
|
|
42
|
Khanna D, Sethi G, Ahn KS, Pandey MK,
Kunnumakkara AB, Sung B, Aggarwal A and Aggarwal BB: Natural
products as a gold mine for arthritis treatment. Curr Opin
Pharmacol. 7:344–351. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Singh S, Aggarwal BB and Aggarwal B:
Activation of transcription factor NF-kappa B is suppressed by
curcumin (diferuloylmethane) [corrected]. J Biol Chem.
270:24995–25000. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Zhao FL, Yang GH, Xiang S, Gao DD and Zeng
C: In silico analysis of the effect of mutation on epidermal growth
factor receptor in non-small-cell lung carcinoma: from mutational
analysis to drug designing. J Biomol Struct Dyn. 35:427–434. 2017.
View Article : Google Scholar
|
